Fig 1.
Bimodal distribution of age according to prescribed treatment.
Patients of 31–45 years of age were mostly treated with MTX, while patients>45 years were treated with LEF.
Fig 2.
Side effects exhibited by patients after methotrexate and leflunomide treatment.
Fatigue, headache and body rashes are more prominent side effects of RA treatments.
Fig 3.
Comparison of weight gain in leflunomide and methotrexate treated patients with control.
***indicate significance at P<0.0001.
Table 1.
Percentage variations in BMI, blood pressure, spot oxygen saturation, and pulse rate in healthy individuals, methotrexate and leflunomide treated rheumatoid arthritis patients.
Fig 4.
Pulse rate (BPM) (A) and Spot oxygen saturation (B) in rheumatoid arthritis patients on >10 mg and >20 mg dose of methotrexate and leflunomide.
Fig 5.
(A-F): Average concentrations of AST, ALP, ALT, Total bilirubin, direct bilirubin (E) and indirect bilirubin. *, **, *** indicate significance at P< 0.05, 0.01 and P< 0.001.
Table 2.
Percentage variations in Liver enzymes, Bilirubin, and Kidney function tests in healthy individuals, methotrexate and leflunomide treated rheumatoid arthritis patients.
Fig 6.
(A-E): Average levels of Blood Urea Nitrogen (BUN), uric acid, urinary urea, serum creatinine, and GFR. *, **, ***indicate significance at P<0.05, 0.01 and P<0.001.